Sim&Cure has closed a €10 million series extension round, with the proceeds set to support the company’s international expansion—particularly in China and the Asia-Pacific region—accelerate the development of its software portfolio, and strengthen its research and development (R&D) and commercial teams.
The series extension was supported by historical investors Elaia and IT Translation Investissement, alongside IRDI Capital Investissement, SWEN Capital Partners, Sofilaro, Tudigo and Holnest.
“This funding is a testament to our team’s dedication and to the continued trust of our investors, especially Elaia and IT Translation Investissement, who have believed in our journey from the very beginning,” said Mathieu Sanchez, chief executive officer (CEO) and co-founder of Sim&Cure. “With their support, and that of our new partners […], we are well positioned to accelerate our global development and pursue our mission to disrupt the management of cerebral aneurysms by promoting a preventive and personalised approach.”
A press release from the company notes that, despite “major progress” in imaging and interventional techniques, brain aneurysms remain frequently underdiagnosed and are often detected after rupture, which complicates treatment and increases healthcare costs.
Sim&Cure develops software solutions designed to assist healthcare professionals in planning endovascular procedures more safely and efficiently through patient-specific simulation. By leveraging digital twin and artificial intelligence (AI) technologies, the company aims to support better-informed clinical decision-making while contributing to improved procedure planning.
The company’s flagship product, Sim&Size, provides physicians with a patient-specific digital representation that allows them to simulate multiple endovascular treatment scenarios prior to intervention. This approach is intended to help clinicians anticipate technical challenges and evaluate device positioning options.
Sim&Size is used in more than 45 countries and has been deployed in collaboration with over 700 healthcare professionals, contributing to more than 35,000 treatment planning procedures. Strategic collaborations with industry leaders like Siemens Healthineers and Philips aim to integrate Sim&Cure’s technology into advanced imaging ecosystems, bringing simulation tools closer to physicians’ existing environments, the company also states.
Additionally, Sim&Cure has diversified its product portfolio with the launch of Sim&Train—a training platform using 3D printing technology—and, more recently, Sim&Predict, which is an AI software intended to automatically detect cerebral aneurysms on medical images.
